2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155133
    COX-2-IN-34 2788578-71-0 98.87%
    COX-2-IN-34 (compound 8a) is a selective and orally active inhibitor of COX-2 , with an IC50 of 0.42 μM. COX-2-IN-34 has no gastric ulcer toxicity but has anti-inflammatory effects.
    COX-2-IN-34
  • HY-155151
    RIPK2/3-IN-1
    RIPK2/3-IN-1 is a potent dual RIPK2/3 kinases inhibitor with IC50 values of 3 nM and 117 nM, respectively. RIPK2/3-IN-1 is against RIPK2 with IC50 value 14 nM in 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay.
    RIPK2/3-IN-1
  • HY-155159
    COX-2/15-LOX-IN-2
    COX-2/15-LOX-IN-2 is a potent dual COX-2 and 15-LOX inhibitor with IC50 values of 0.065?μM and 1.86?μM, respectively. COX-2/15-LOX-IN-2 has potent antioxidant activity.
    COX-2/15-LOX-IN-2
  • HY-155160
    COX-2/15-LOX-IN-3
    COX-2/15-LOX-IN-3 (compound 5k) is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-3 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS, and NO), with specific anti-inflammatory activity.
    COX-2/15-LOX-IN-3
  • HY-155161
    COX-2/15-LOX-IN-4
    COX-2/15-LOX-IN-4 (compound 5i) is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-4 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS) with specific anti-inflammatory activity.
    COX-2/15-LOX-IN-4
  • HY-155182
    HDAC-IN-62
    HDAC-IN-62 (Compound 5) a HDAC inhibitor, with IC50s of 0.78, 1.0, 1.2? μM for HDAC6/8/11 respectively. HDAC-IN-62 inhibits-induced microglial activation by the initiation of autophagy, and inhibits nitric oxide production. HDAC-IN-62 has anti-inflammatory and anti-depressant effects. HDAC-IN-62 inhibits microglial activation in mouse brain.
    HDAC-IN-62
  • HY-155183
    A3AR agonist 1
    A3AR agonist 1 (Compound 12) is an A3AR agonist (Ki: 25.8 nM). A3AR agonist 1 stimulates β-arrestin2 recruitment, with an EC50 value of 5.17 nM. A3AR agonist 1 can be used for research of inflammatory diseases, ischemia, cancer, neuropathic pain, liver diseases, etc.
    A3AR agonist 1
  • HY-155184
    A3AR agonist 2
    A3AR agonist 2 (Compound 19) a selective A3AR agonist (Ki: 22.1 nM). A3AR agonist 2 stimulates β-arrestin2 recruitment, with EC50 value of 4.36 nM. A3AR agonist 2 can be used for research of inflammatory diseases, ischemia, cancer, neuropathic pain, liver diseases, and other chronic conditions. A3AR agonist 2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    A3AR agonist 2
  • HY-155192
    Galectin-3/galectin-8-IN-2
    Galectin-3/galectin-8-IN-2 (Compound 57) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 12.8 μM and 2.06 μM respectively. Galectin-3/galectin-8-IN-2 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-2 can be used for research of cancer and tissue fibrosis.
    Galectin-3/galectin-8-IN-2
  • HY-155199
    PDE1-IN-5 2982945-34-4
    PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor (IC50: 15 nM). PDE1-IN-5 has anti- inflammatory activity, and inhibits expression of iNOS, TNF-α, IL-1α, IL-1β, and IL-6 induced by LPS. PDE1-IN-5 has anti-inflammatory bowel disease (IBD) effects in the dextran sodium sulfate (DSS)-Induced colitis mice model. PDE1-IN-5 can be used for research of IBD.
    PDE1-IN-5
  • HY-155204
    LTB4-IN-2
    LTB4-IN-2 (Comopund 6x) is a Leukotriene B4 (LTB4) inhibitor. LTB4-IN-2 inhibits Leukotriene B4 formation (IC50: 1.15 μM) by selectively targeting 5-Lipoxygenase-activating protein (FLAP). LTB4-IN-2 can be used for anti-inflammatory research.
    LTB4-IN-2
  • HY-155228
    LK-44
    hCES2A-IN-2 (Compound 44) is an orally active human carboxylesterase 2 (hCES2A) inhibitor (IC50: 5.02 μM). hCES2A-IN-2 improves Irinotecan (HY-16562)-induced delayed diarrhea.
    LK-44
  • HY-155236
    Ancistrotecine B
    Ancistrotecine B (Compound 2) is a Nav1.7 channel inhibitor (IC50: 0.73 μM). Ancistrotecine B relieves inflammatory pain in mice.
    Ancistrotecine B
  • HY-155243
    12R-LOX-IN-1 857758-13-5
    12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC50: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research.
    12R-LOX-IN-1
  • HY-155282
    FASN-IN-6 3032387-88-2
    FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively.
    FASN-IN-6
  • HY-155286
    (7S,8R,17S)-RCTR1 2095607-49-9
    (7S,8R,17S)-RCTR1 is a specialized pro-resolving mediator, that exhibits anti-inflammatory and anti-infective activities. (7S,8R,17S)-RCTR1 promotes pathogen clearance, wound healing, tissue repair and regeneration.
    (7S,8R,17S)-RCTR1
  • HY-155300
    BLT2 antagonist-1 2069220-61-5
    BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC50 of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a Ki value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease.
    BLT2 antagonist-1
  • HY-155306
    TGR5 agonist 3 2148317-51-3
    TGR5 agonist 3 (compound 8), a Cholic acid derivative, is a selective TGR5 agonist with an EC50 of 5 μM.
    TGR5 agonist 3
  • HY-155307
    TGR5 agonist 4
    TGR5 agonist 4 (compound 19), a cholic acid derivative, is a selective TGR5 agonist with an EC50 of 4 μM.
    TGR5 agonist 4
  • HY-155311
    NKG2D-IN-1
    NKG2D-IN-1 (compound 21) is a natural killer group 2D receptor (NKG2D) inhibitor with IC50s of 0.3 µM and 0.7 µM in NKG2D/MICA and ULBP6 TR-FRET assays, respectively.
    NKG2D-IN-1
Cat. No. Product Name / Synonyms Application Reactivity